No Data
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240
Wells Fargo analyst Larry Biegelsen maintains $Insulet(PODD.US)$ with a buy rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 58.9% and a tot
Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com
An automated insulin pump markedly improved the health of patients with Type 2 diabetes, the pump maker Insulet told a conference last weekend. The company is asking regulators to clear its Omnipod pump as the first automated dispenser for the 30 million Americans with the disorder.
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks